You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 105 No. 6, June 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  CLINICAL SCIENCES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Intravenous Pulse Methylprednisolone in Scleritis

Peter McCluskey, MBBS, FRACO, FRACS; Denis Wakefield, MD, FRACP, FRCPA

Arch Ophthalmol. 1987;105(6):793-797.


Abstract

• We treated 14 patients with scleritis with intermittent pulse doses of intravenous methylprednisolone. There were 13 patients with anterior scleritis and one patient with posterior scleritis. A grading system was developed to quantitate the degree of scleral inflammation and to follow up the response to treatment. A standard protocol of intravenous administration of methylprednisolone was followed, commencing with 1 g on three occasions in the first week. Additional immunosuppression was required in six patients. The therapy improved the patients' conditions, with a significant reduction in the severity of the scleritis in all patients. Side effects included psychological disturbances, hypertension, and elevated glucose levels, but no patient required cessation of treatment. Pulse methylprednisolone treatment alone or in combination with other immunosuppressive agents is an effective therapy in severe scleritis and has fewer potential side effects than more conventional regimens of corticosteroid administration.



Author Affiliations

From the Laboratory of Ocular Immunology, School of Pathology, University of New South Wales, Kensington (Drs McCluskey and Wakefield); the Ophthalmology Department, St Vincent's Hospital, Sydney (Dr McCluskey); the Department of Immunology, Prince of Wales Hospital, Sydney (Dr Wakefield); and the Uveitis Research Clinic, Sydney Eye Hospital (Dr Wakefield); Australia.


Footnotes

Accepted for publication Feb 20, 1987.

Reprint requests to School of Pathology, University of New South Wales, PO Box 1, Kensington, NSW 2033, Australia (Dr Wakefield).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Giant Cell Arteritis: Corticosteroids, Temporal Artery Biopsy, and Blindness
Weinberg et al.
Arch Fam Med 1994;3:623-627.
ABSTRACT  

Side Effects of Glucocorticoid Treatment: Experience of the Optic Neuritis Treatment Trial
Chrousos et al.
JAMA 1993;269:2110-2112.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.